RE: Novo buying companies19 Nov 2021 17:33
I just thought it was a fair price for which etx currently have in cash, technology, and clinical trials. Also limited shares available.
Yes potentially this company can grow quick, but can't really compare to what Dicerna have. For a start it has Cash Position – As of September 30, 2021, $646.6 million in cash, cash equivalents.